Liothyronine (T3) / Cytomel

Overview

Liothyronine is the biologically active form of thyroid hormone (T3). While the thyroid gland secretes both T4 (levothyroxine) and T3, approximately 80% of circulating T3 is produced peripherally via type-1 and type-2 deiodinase conversion of T4. Liothyronine bypasses this enzymatic step entirely, delivering active hormone directly to receptor sites without requiring peripheral conversion — a pharmacokinetic advantage when conversion efficiency is compromised or when precise control is required.

FDA-approved indications include hypothyroidism (when T4 alone is insufficient or poorly tolerated) and TSH suppression in thyroid cancer management. Within research contexts, the AAS + T3 combination has been a mainstay of cutting protocols for decades. Supraphysiological T3 raises basal metabolic rate (BMR) by 10–40% depending on dose, dramatically accelerating fat oxidation and thermogenesis through mitochondrial uncoupling and Na+/K+-ATPase upregulation.

The 24-hour half-life (versus 7 days for levothyroxine) provides daily dose-titration control: effects can be escalated or attenuated within 2–3 days rather than waiting weeks, making T3 the preferred compound when precision matters. However, this same short half-life means missed doses produce rapid drops in circulating T3 and symptomatic hypothyroid rebound.

The critical pharmacodynamic distinction: physiological T3 is required for normal protein synthesis (T3 is obligatory for GH-mediated IGF-1 expression and mTOR pathway activity). At supraphysiological doses, however, the equation reverses — protein breakdown rate exceeds synthesis capacity, making T3 net catabolic. AAS co-use partially offsets this through IGF-1/mTOR anabolic signaling but does not fully compensate at doses above 75 mcg/day. This is the defining tension of T3 research protocols: the metabolic benefit is real, and so is the lean mass cost.

Mechanism of Action

T3 exerts its effects through nuclear thyroid hormone receptors (TR-α and TR-β), which are ligand-activated transcription factors. Unlike peptide hormones that act on cell surface receptors, T3 crosses the cell membrane and binds directly to nuclear TRs, forming receptor-hormone complexes that interact with thyroid hormone response elements (TREs) on DNA to regulate gene transcription.

Key transcriptional effects:

• Na+/K+-ATPase upregulation — the primary thermogenic mechanism. Increased pump activity consumes ATP, driving mitochondrial respiration and generating heat. This is the dominant pathway behind T3-mediated BMR elevation.
• β-adrenergic receptor density increase — T3 transcriptionally upregulates β1 and β2 adrenergic receptor expression, sensitizing tissues to catecholamines (epinephrine, norepinephrine). This amplifies sympathomimetic effects: tachycardia, tremor, anxiety, thermogenesis.
• Mitochondrial biogenesis — T3 drives PGC-1α expression and mitochondrial DNA replication, increasing oxidative capacity in skeletal muscle and adipose tissue.
• Uncoupling protein (UCP) upregulation — UCP1 in brown adipose tissue, UCP2/3 in skeletal muscle and other tissues. UCPs dissipate the mitochondrial proton gradient as heat rather than ATP synthesis — a direct thermogenic futile cycle.
• Lipogenic and lipolytic effects — at physiological levels T3 drives both synthesis and turnover. At supraphysiological levels: net fat mobilization predominates through upregulation of hormone-sensitive lipase and fatty acid oxidation enzymes.

Cardiac effects (predominantly TR-α in cardiomyocytes): T3 directly upregulates myosin heavy chain α (fast, high ATPase activity) and downregulates β isoform. Combined with β-adrenergic receptor upregulation, this produces: positive chronotropy (elevated resting heart rate), positive inotropy (increased contractility), and increased cardiac output. These effects are dose-dependent and are the mechanistic foundation for T3's cardiac risk profile.

The catabolic dose-response: At physiological levels, T3 is required for GH-stimulated IGF-1 synthesis and normal mTOR activity — protein synthesis is impaired in hypothyroid subjects. As T3 rises above physiological range: direct transcriptional upregulation of protein degradation pathways (ubiquitin-proteasome system, lysosomal autophagy) accelerates. At supraphysiological doses (>50–75 mcg/day without anabolic support), the net effect is catabolism — measurable lean mass loss by DEXA within 4–6 weeks.

Clinical Protocol Context

Liothyronine (synthetic T3) is the most potent thyroid hormone preparation studied in clinical endocrinology. Combination T4/T3 therapy has been evaluated in multiple RCTs, including Saravanan et al. (2005), which assessed quality-of-life outcomes in hypothyroid patients on levothyroxine alone versus T4+T3 combination. The European Thyroid Association consensus (Wiersinga et al., 2012) and ATA guidelines (Jonklaas et al., 2014) provide framework for T3 use. In AAS research contexts, T3's effect on basal metabolic rate and its narrow therapeutic index make monitoring critical.

Dosing & Protocol Frameworks

Standard research protocol:

• Weeks 1–2: 25 mcg/day (ramp phase)
• Weeks 3–8: 50 mcg/day (maintenance phase)
• Week 9: 25 mcg/day (taper)
• Week 10: Stop

Maximum dose: 75 mcg/day. Above this threshold, the risk-to-benefit ratio shifts clearly toward harm — cardiac risk increases non-linearly, lean mass losses become difficult to offset even with robust anabolic support, and TSH suppression duration post-cycle extends significantly.

Duration: 8–12 weeks per protocol maximum. Longer cycles extend the post-cycle thyroid recovery period (TSH normalization may take 8–16 weeks after extended high-dose use).

Ramp and taper protocol is mandatory: Abrupt T3 initiation at full dose triggers rapid sympathomimetic effects (palpitations, anxiety, tremor) before the body adapts. Abrupt discontinuation precipitates symptomatic hypothyroidism during the 4–8 week period required for endogenous thyroid axis recovery — the pituitary-thyroid axis was suppressed throughout the protocol and requires time to restore normal secretion. Subjects experience fatigue, cold intolerance, bradycardia, depression, and cognitive slowing during recovery. The taper reduces the severity and duration of this transition.

Concurrent AAS: Anabolic support is effectively required for any protocol above 50 mcg/day if lean mass preservation is a research variable. Testosterone (>200 mg/week) or nandrolone provide the most studied protection via IGF-1 upregulation. Oxandrolone's mTOR activity makes it a commonly researched addition, though its androgen-to-anabolic profile is distinct.

Absorption considerations: T3 bioavailability is approximately 95%, making it highly reliable. Take at consistent timing relative to food — food delays but does not significantly impair absorption. Critically: separate from calcium, iron, and magnesium by at least 4 hours. These divalent cations chelate thyroid hormones in the GI tract, significantly reducing absorption and producing unpredictable dose delivery.

Bloodwork & Monitoring

Thyroid panel: TSH, free T3 (fT3), free T4 (fT4), and reverse T3 (rT3) at baseline before protocol initiation and every 4 weeks during the protocol.

• TSH suppression to near-zero: Expected and normal finding during exogenous T3 administration. Exogenous T3 suppresses hypothalamic TRH and pituitary TSH secretion via negative feedback — this is the mechanism, not a complication. TSH near zero during T3 use indicates appropriate suppression, not pathology.
• Free T3: Will be elevated above normal range at research doses — the driver of all metabolic effects being studied.
• Free T4: Will be suppressed (TSH-driven T4 production decreases). Low fT4 during T3 use is expected.
• Reverse T3 (rT3): Monitors stress-mediated deiodinase shifts. Caloric restriction independently elevates rT3 (via cortisol-driven type 3 deiodinase activity), which can blunt T3 efficacy. Elevated rT3 with normal or high fT3 suggests rT3 competition at receptor sites.

Cardiovascular monitoring:

• Resting heart rate (daily): Target <90 bpm during T3 use. Heart rate is the most sensitive early indicator of excessive cardiac stimulation. If consistently above 95 bpm: reduce dose by 25 mcg and reassess at 1 week.
• Blood pressure: T3 increases cardiac output (stroke volume × heart rate). In subjects already managing AAS-induced hypertension, T3 can compound the problem. Recheck every 4 weeks or with any dose change.
• EKG: At baseline if cardiac history is present, with prolonged AAS use (left ventricular hypertrophy risk), or if arrhythmia symptoms (palpitations, irregular pulse, near-syncope) develop during protocol.

Body composition: DEXA scan for protocols exceeding 16 cumulative weeks of T3 use — bone mineral density assessment (chronic supraphysiological T3 stimulates osteoclast activity) and lean mass quantification to assess catabolism magnitude.

Side Effects & Risks

Common (dose-dependent):

• Palpitations — the most frequent reported symptom. Driven by T3-mediated chronotropy and β-adrenergic upregulation. Usually benign at moderate doses; warrants investigation if irregular (possible atrial fibrillation) or severe.
• Tremor — fine hand tremor from β-adrenergic receptor upregulation and catecholamine sensitization. Dose-dependent; typically resolves with taper.
• Sweating and heat intolerance — direct consequence of thermogenesis upregulation. Common at >50 mcg/day and expected.
• Anxiety and irritability — β-adrenergic sensitization combined with sympathomimetic state. Can be exacerbated by concurrent stimulant use.
• Insomnia — elevated metabolic rate and adrenergic tone disrupt sleep architecture at higher doses.
• Diarrhea and increased bowel motility — T3 increases GI smooth muscle contractility. Usually mild; can affect drug absorption timing if severe.

Serious risks:

• Cardiac arrhythmias — including atrial fibrillation. The highest-risk scenario is supraphysiological T3 in a subject with AAS-induced left ventricular hypertrophy (LVH). LVH from prolonged AAS use produces atrial remodeling and increased arrhythmia susceptibility; direct T3 chronotropy and β-receptor upregulation compound this risk significantly. Prolonged AF can lead to atrial thrombus formation and stroke.
• Lean mass loss — measurable by DEXA at doses above 50 mcg/day without adequate anabolic support. The combination of protein catabolism acceleration and the caloric deficit typical of cutting protocols creates cumulative lean tissue loss that is difficult to fully recover in the subsequent phase.
• Bone demineralization — chronic supraphysiological T3 directly stimulates osteoclast activity via TR-α receptors in bone. Relevant for protocols with repeated or extended T3 cycles. Cumulative exposure matters more than any single protocol.
• Post-cycle thyroid suppression — the hypothalamic-pituitary-thyroid axis requires 4–16 weeks to restore normal function after a T3 protocol. During this recovery period subjects experience transient but often significant hypothyroid symptoms. Recovery time scales with dose and duration of prior T3 use.

Drug Interactions

• Warfarin: T3 increases warfarin anticoagulant effect by upregulating catabolism of vitamin K-dependent clotting factor synthesis. Subjects on anticoagulation therapy require INR monitoring and likely warfarin dose reduction when initiating T3. Failure to monitor can result in serious bleeding events.
• Digoxin: T3 increases cardiac metabolic demand and heart rate. In subjects with marginal cardiac reserve — particularly those with AAS-induced cardiomyopathy or impaired diastolic function — increased demand may precipitate toxicity or decompensation. Combined T3 + digoxin should be considered high-risk.
• Sympathomimetics (caffeine, ephedrine, clenbuterol, DMAA, synephrine): T3 upregulates β-adrenergic receptor density, amplifying the cardiovascular response to all catecholamine-acting compounds. Chronotropy and blood pressure responses to stimulants are significantly greater during T3 use. This combination is the most frequently encountered cardiac risk factor in research protocol accidents — the "fat burner stack" combining T3 + clenbuterol + ephedrine substantially increases arrhythmia risk.
• AAS (anabolic protection context): Testosterone and nandrolone provide partial protection against lean mass loss through IGF-1/mTOR pathway upregulation. This protection is real but dose-limited — it does not fully prevent catabolism at T3 doses above 75 mcg/day. Oxandrolone's direct mTOR activity provides additive protection; its profile makes it a commonly co-researched compound for this purpose.
• Insulin and GH: T3 enhances GH-mediated IGF-1 production at physiological levels. In research protocols combining GH + insulin + T3, metabolic effects are substantially amplified. This combination requires experienced research oversight — the interplay of these compounds on glucose metabolism, anabolism, and catabolism is complex and individually variable.
• Calcium, iron, magnesium (supplements): Divalent cations form insoluble chelates with thyroid hormones in the GI tract, reducing T3 absorption by 25–40% when taken concurrently. Supplement timing must be separated by at least 4 hours from T3 dosing — particularly relevant during cutting protocols where supplement regimens are typically intensive.

Research Literature

• Bianco et al. (Endocrine Reviews, 2019) — Comprehensive review of T3 metabolism, deiodinase enzymology, and thyroid hormone receptor biology. The definitive reference for understanding T3/T4 interconversion and tissue-specific receptor effects.
• Burger et al. (J Clin Endocrinol Metab, 1976) — Characterized dose-response relationship between exogenous T3 administration and basal metabolic rate in human subjects. Foundational quantitative data supporting the 10–40% BMR elevation range at supraphysiological doses.
• Biondi & Cooper (NEJM, 2012) — "The Clinical Significance of Subclinical Thyroid Dysfunction" — essential context for understanding TSH, fT3, and fT4 relationships across the physiological range. Directly applicable to monitoring protocols.
• Katzeff (Endocrinology, 1988) — Examined T3-induced protein turnover at supraphysiological doses, quantifying the catabolism mechanism and identifying the dose thresholds at which protein breakdown rate exceeds synthesis. Core reference for the catabolic ceiling framework.
• Yeap et al. (Eur J Endocrinol, 2021) — Prospective data on thyroid function parameters and body composition outcomes in adults — contextualizes what fT3 levels correspond to specific lean mass and fat mass trajectories.
• Klein & Ojamaa (NEJM, 2001) — "Thyroid Hormone and the Cardiovascular System" — mechanistic review of T3 cardiac effects (TR-α chronotropy, myosin isoform switching, β-receptor upregulation) that directly underpins the cardiac arrhythmia risk profile.